Aducanumab Subanalysis Bolsters Phase III Trials in Very Early Alzheimer’s Disease

The primary end point is change from baseline on the CDR-SB. Secondary end points are change on the MMSE, the Alzheimer’s Disease Assessment Study cognitive scale (ADAS-cog), and the Alzheimer’s Disease Cooperative Study activities of daily living and mild cognitive impairment scales (ADCS ADL, MCI). In addition, a subset of patients will undergo additional PET amyloid imaging as a tertiary end point.

—Michele G. Sullivan